GIMBHI’s daily mental health update — 7/28/26

🤝 Mindoula buys Valera Health, Janus Healthcare Partners (Chris Larson, Behavioral Health Business) — 07/22/26
TL;DR: Maryland-based Mindoula acquired Valera Health (300+ behavioral health providers) and Janus Healthcare Partners, deepening its clinical footprint, adding psychiatric collaborative care capabilities, and accelerating its push into value-based care.

💊 Otsuka receives FDA approval for first-in-class SIMTRIYO (centanafadine) for ADHD (Otsuka) — 07/24/26
TL;DR: The FDA approved Otsuka’s SIMTRIYO (centanafadine), the first norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD in adults and children 6+, backed by four Phase 3 trials; it carries boxed warnings for pediatric suicidal ideation and abuse.

🧠 Headspace expands specialty care ecosystem to support neurodiversity, eating disorders, and high-acuity care (Headspace) — 07/21/26
TL;DR: Headspace partnered with Charlie Health, Cortica, Prosper, and Equip to give members and their dependents coordinated referral pathways to specialty care for autism, eating disorders, substance use, and other complex needs.

🩺 Teladoc Health introduces a virtual care practice built around the person (Teladoc Health) — 07/23/26

TL;DR: Teladoc launched Teladoc One, a connected virtual care model pairing multidisciplinary teams with always-on AI to treat each patient holistically rather than one disease at a time, with 100% of its fees tied to outcomes.